Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 90 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Contraception, Menorrhagia
Interventions
ESS305 (Essure, BAY1454032), NovaSure
Device · Procedure
Lead sponsor
Bayer
Industry
Eligibility
21 Years to 50 Years · Female only
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
17
States / cities
Aurora, Colorado • Ocala, Florida • Decatur, Illinois + 14 more
Conditions
Uterine Fibroid, Endometriosis
Interventions
Not listed
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
660 participants
Timeline
2018 – 2020
U.S. locations
37
States / cities
Mobile, Alabama • Mesa, Arizona • Huntington Beach, California + 31 more
Conditions
Menorrhagia, Dysfunctional Uterine Bleeding, Leiomyoma, Pelvic Pain, Endometriosis
Interventions
Conventional Laparoscopic Hysterectomy (LH), Robot Assisted Hysterectomy
Procedure
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Hershey, Pennsylvania
Conditions
Menorrhagia
Interventions
Extended treatment regimen using Her Option Cryotherapy
Device
Lead sponsor
CooperSurgical Inc.
Industry
Eligibility
30 Years to 100 Years · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
7
States / cities
Phoenix, Arizona • Wellington, Florida • Burlington, Massachusetts + 4 more
Completed Not applicable Interventional

Post Market TRUST - U.S.A. Study

NCT02163525
Conditions
Symptomatic Uterine Fibroids
Interventions
Global Fibroid Ablation (GFA), Abdominal or Laparoscopic Myomectomy, Uterine Artery Embolization (UAE)
Procedure
Lead sponsor
Acessa Health, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
9
States / cities
Santa Monica, California • Walnut Creek, California • Augusta, Georgia + 6 more
Conditions
Heavy Menstrual Bleeding
Interventions
Volta System
Device
Lead sponsor
Spark Biomedical, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Dallas, Texas
Completed Not applicable Interventional Accepts healthy volunteers

Surgical Success After Laparoscopic vs Abdominal Hysterectomy

NCT01793584
Conditions
Metrorrhagia, Menorrhagia, Leiomyoma, Adenomyosis, Pelvic Pain, Endometriosis, Pelvic Inflammatory Disease
Interventions
Laparoscopic hysterectomy, Abdominal hysterectomy
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Von Willebrand Diseases
Interventions
recombinant von Willebrand factor, tranexamic acid
Drug
Lead sponsor
Margaret Ragni
Other
Eligibility
13 Years to 45 Years · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
19
States / cities
Gilbert, Arizona • Orange, California • San Francisco, California + 16 more
Conditions
Uterine Fibroids
Interventions
Elagolix, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
45
States / cities
Birmingham, Alabama • Searcy, Arkansas • La Mesa, California + 35 more
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

How Does Perimenopausal Menorrhagia Affect Women's Quality of Life and Cognitive Function?

NCT06798584
Conditions
Iron Deficiency Anemia Treatment, Iron Deficiency, Iron Deficiency (Without Anemia)
Interventions
FeoSol Original Iron Supplement Tablets, 21st Century Gelatin Capsules
Dietary Supplement
Lead sponsor
Purdue University
Other
Eligibility
18 Years and older · Female only
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
West Lafayette, Indiana
Completed Phase 2Phase 3 Interventional Results available

RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding

NCT02829957
Conditions
Venous Thromboembolism, Menstruation
Interventions
Apixaban, Rivaroxaban
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Indianapolis, Indiana
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Alternate Day Versus Daily Oral Iron Therapy in Adolescents

NCT05007899
Conditions
Iron Deficiency Anemia, Heavy Menstrual Bleeding, Abnormal Uterine Bleeding
Interventions
Ferrous sulfate
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
9 Years to 22 Years · Female only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Houston, Texas
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Completed Not applicable Interventional Results available

Sonography Guided Transcervical Ablation of Uterine Fibroids

NCT02228174
Conditions
Menorrhagia
Interventions
Intrauterine Ultrasound-Guided Radiofreq. Ablation System
Device
Lead sponsor
Gynesonics
Industry
Eligibility
25 Years to 50 Years · Female only
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
22
States / cities
Phoenix, Arizona • Denver, Colorado • Newark, Delaware + 19 more
Conditions
Heavy Menstrual Bleeding, Abnormal Uterine Bleeding, Menorrhagia
Interventions
Cerene
Device
Lead sponsor
Channel Medsystems
Industry
Eligibility
25 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
West Orange, New Jersey • Cincinnati, Ohio
Conditions
Heavy Menstrual Bleeding, Bleeding Disorder, Von Willebrand Diseases
Interventions
Levonorgestrel Intrauterine System, Norethindrone Acetate
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
10 Years to 24 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
9
States / cities
Palo Alto, California • Aurora, Colorado • Atlanta, Georgia + 5 more
Conditions
Hemophilia, Menstrual Flow Excessive
Interventions
Recombinant FVIII Fc fusion product Eloctate, Recombinant FIX Fc fusion product Alprolix, Patient-operated diagnostic device for anemia AnemoCheck.
Drug · Device
Lead sponsor
Emory University
Other
Eligibility
14 Years to 55 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Uterine Fibroids, Heavy Menstrual Bleeding
Interventions
OBE2109, Placebo to match OBE2109, Placebo to match Add-back, Add-back
Drug
Lead sponsor
ObsEva SA
Industry
Eligibility
18 Years and older · Female only
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
23
States / cities
Chino, California • Huntington Park, California • San Diego, California + 19 more
Conditions
Premenstrual Syndrome, Menstrual Cycle, Menstrual Distress (Dysmenorrhea), Menstrual Bleeding, Heavy
Interventions
Moderate Aerobic Exercise
Behavioral
Lead sponsor
University of Colorado, Colorado Springs
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Colorado Springs, Colorado
Conditions
Menorrhagia, Blood Coagulation Disorders, Blood Platelet Disorders, Von Willebrand Disease, Hematologic Disease
Interventions
Tranexamic Acid, Desmopressin Acetate
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years to 50 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
6
States / cities
Atlanta, Georgia • East Lansing, Michigan • Rochester, Minnesota + 3 more
Conditions
Menorrhagia
Interventions
AEGEA Vapor System(TM)
Device
Lead sponsor
Aegea Medical, Inc.
Industry
Eligibility
30 Years to 50 Years · Female only
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
12
States / cities
New Britain, Connecticut • Orlando, Florida • Wellington, Florida + 9 more
Conditions
Metrorrhagia, Pelvic Pain, Menorrhagia, Leiomyoma
Interventions
Myfembree Oral Product
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
6
States / cities
Chicago, Illinois • Flossmoor, Illinois • Orland Park, Illinois + 1 more
Conditions
Symptomatic Uterine Fibroids and Adenomyosis
Interventions
IV Ibuprofen, IV Acetaminophen, Intravenous placebo/Intravenous placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 60 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Los Angeles, California • Santa Monica, California
Completed Not applicable Interventional Results available

Registry Study of Genesys HTA for Treatment of Menorrhagia

NCT01197547
Conditions
Menorrhagia
Interventions
Genesys HTA
Device
Lead sponsor
Minerva Surgical, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,014 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
19
States / cities
San Diego, California • Newark, Delaware • Athens, Georgia + 16 more